Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, the rest of North America, the United Kingdom, the rest of Europe, and internationally. The company is headquartered in Englewood, Colorado.
105 articles
Innospec Inc (IOSP) maintains a long-term positive bias despite neutral near-term readings. AI models propose trading strategies including momentum breakouts and risk-hedging with a 26.9:1 risk-reward
Innospec Inc won the Regulatory & Compliance Excellence award at the Cosmetics Business Innovation Awards for its ethical, non-animal testing methods for cosmetic ingredients, potentially influencing
Innospec Inc. shares reached a 52-week high of $95.07 following strong Q2 2026 financial results that surpassed earnings and revenue expectations.
Innospec Inc met Q2 2023 EPS expectations at €1.11 but missed revenue projections by €13.47 million, reporting €415.77 million with 2.74% YoY growth. Next earnings are scheduled for November 10, 2026.
Innospec reported strong first-half 2026 results with increased sales and net income, alongside ongoing share repurchase activities. Analysts suggest the stock may be 6% undervalued following these fi
Innospec Inc. reported strong Q2 2026 earnings and completed a $34.87 million share repurchase program. The company focuses on specialized chemicals earnings despite raw material volatility.
Innospec Inc reported Q1 2024 earnings with an EPS beat of $1.75 against consensus, while revenue of $500.20 million slightly missed expectations. The release includes access to the earnings call and
Innospec Inc. shares reached a 52-week high of $94.67 following strong Q2 2026 financial results that exceeded earnings and revenue expectations despite near-term supply constraints.
Innospec reported Q2 2026 sales of US$491.4 million, achieving a debt-free balance sheet that drove a 7.5% stock rise. While authorizing a US$75 million share repurchase, the company noted risks from
Innospec Inc. released its Q2 2026 earnings call presentation, reporting EPS of $1.27 and revenue of $491.40 million, surpassing analyst estimates.
Innospec Inc. reported second-quarter 2026 adjusted earnings of $1.27 per share and revenues of $491.4 million, surpassing consensus estimates. Growth was broad-based across its Performance Chemicals,
The Public Employees Retirement System of Ohio significantly reduced its stake in Innospec Inc. by 96.6% in Q1, even as the company reported strong quarterly earnings beating analyst estimates.
Janus Henderson Group PLC reduced its stake in Innospec Inc. by 11.7% in Q1, while other institutions increased positions. Innospec reported strong quarterly earnings with $1.27 EPS and 11.8% revenue
Arrowstreet Capital increased its stake in specialty chemical firm Innospec Inc. by 196.5% in Q1. This follows Innospec's strong quarterly earnings of $1.27 per share and 11.8% revenue growth, pushing
Innospec Inc reported strong Q2 2026 earnings with double-digit sales growth, despite margin pressures from supply constraints. Management plans facility expansions by late 2026 to boost capacity and
Innospec reported strong Q2 2026 financial results with revenue rising 12% to $491.4 million. Net income reached $30.8 million while maintaining a debt-free balance sheet and returning capital to shar
Innospec Inc stock reached a new 52-week high of $92.31 following strong Q2 2026 results that exceeded analyst expectations with $1.27 adjusted EPS. The company holds a $2.26 billion market cap, with
Innospec Inc exceeded Q2 2026 forecasts with adjusted EPS of $1.27 and revenue of $491.4 million, driving a 2.7% stock rise. Management highlighted double-digit segment growth and plans to boost Perfo
Innospec Inc. reported strong Q2 2026 results with revenue of $491.4 million and EPS of $1.25. Growth was driven by volume gains in Fuel Specialties and Performance Chemicals segments alongside operat
Innospec reported strong Q2 2026 earnings with 12% revenue growth to $491.4 million, while Performance Chemicals capacity is set to increase by over 10% following plant repairs.
Innospec Inc. reported strong second-quarter 2026 financial results, with revenues rising 12% to $491.4 million driven by Fuel Specialties and Performance Chemicals segments. The company maintained a
Innospec Inc has released its earnings summary for the quarter ended June 30. The full article is available through Refinitiv on TradingView for subscribers.
Innospec Inc. reported Q2 adjusted EPS of $1.27 and revenue of $491.4 million, both exceeding analyst estimates. These results indicate strong financial performance for the company in the second quart
Allspring Global Investments Holdings LLC disclosed a 7.7% beneficial stake in Innospec Inc. via an amended Schedule 13G filing, holding 1,892,471 shares with sole voting and dispositive power.
Innospec faces expected year-over-year earnings declines despite rising revenue, with negative sentiment suggesting an earnings miss following its removal from Russell indices. Management aims to addr
Innospec Inc (IOSP) ranks 59th in the Chemicals industry with a valuation score of 6.12. Its current P/E ratio is 18.69, while other financial ratios remain undisclosed.
Innospec Inc (IOSP) ranks 12th out of 65 in the Chemicals industry with a risk score of 8.57, exhibiting lower market volatility with a beta value of 0.90.
Innospec Inc. shares declined 1.19% to $84.875 with a $2.10 billion market cap. Analysts maintain a 'Buy' rating with a $99.33 target price, citing strong fundamentals in the Chemicals industry.
Argus Research raised its price target for Innospec Inc. (IOSP) to $90.00, as the chemical and fuel additive manufacturer trades at $84.95. The company operates through three distinct product segments
Innospec Inc (IOSP) ranks 20th in the Chemicals industry with a financial score of 7.76. Quarterly revenue hit $453.20 million, up 2.81% YoY, while net profit increased by 7.32%.
ChemBrief